Passage Bio, INC 10-Q quarterly reports

Passage Bio announces a merger agreement with Remix Therapeutics, plans to wind down gene therapy programs, and reports significant operating losses and cash burn.

Passage Bio's Q1 2026 Form 10-Q filing details ongoing clinical development, a significant workforce reduction, and the initiation of a strategic alternatives review, while highlighting substantial doubt about its going concern.

Passage Bio, a genetic medicines company, reported reduced net losses and extended its cash runway into the first quarter of 2027, driven by strategic restructuring and workforce reductions, while advancing its lead FTD-GRN gene therapy.

Passage Bio reported a reduced net loss and extended its cash runway into Q1 2027, driven by cost-cutting measures and strategic out-licensing, despite ongoing clinical trial risks and the impact of a recent reverse stock split.

Passage Bio reports a net loss of $15.4 million for Q1 2025 and provides updates on its clinical programs, including PBFT02 for FTD-GRN and FTD-C9orf72.

Passage Bio announced its third quarter 2024 financial results, highlighted by a strategic outlicensing of several programs to Gemma Biotherapeutics and a restructuring of its research collaboration with Penn.

Passage Bio announced its second quarter 2024 financial results and a strategic outlicensing agreement with Gemma Biotherapeutics for several key programs.

Passage Bio reported a net loss of $16.7 million for the first quarter of 2024, while advancing its lead clinical program, PBFT02, and pursuing out-licensing opportunities for other assets.